Penserra Capital Management’s Caribou Biosciences CRBU Stock Holding History

Penserra Capital Management’s Portfolio CRBU Stock Details CRBU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-18,672	Closed	-$89K	–	1269
2023 Q3	$89K	Sell	18,672 -6,551	-26%	-$40.6K	﹤0.01%	915
2023 Q2	$107K	Buy	25,223 +6,333	+34%	+$28.5K	﹤0.01%	927
2023 Q1	$100K	Buy	18,890 +4,890	+35%	+$30.5K	﹤0.01%	769
2022 Q4	$87K	Sell	14,000 -9,987	-42%	-$88.9K	﹤0.01%	823
2022 Q3	$253K	Buy	23,987 +18,707	+354%	+$174K	0.01%	561
2022 Q2	$28K	Sell	5,280 -1,388	-21%	-$10.6K	﹤0.01%	1043
2022 Q1	$61K	Buy	+6,668	New	+$70.3K	﹤0.01%	956

Other funds holding CRBU

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

EWM

Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Penserra Capital Management's CRBU Position: Q4 2023 in Review

Penserra Capital Management sold out of Caribou Biosciences (CRBU) in Q4 2023, closing a stake of 18,672 shares — an estimated $89K sold.

Penserra Capital Management first reported a position in CRBU in Q1 2022 and held it in 7 quarters. The position peaked at $253K in Q3 2022. 144 funds tracked by Wall St. Rank hold CRBU as of Q4 2023.

Penserra Capital Management reported no remaining Caribou Biosciences position as of Q4 2023 after selling out during the quarter.
Penserra Capital Management sold 18,672 Caribou Biosciences shares in Q4 2023, an estimated $89K.
Penserra Capital Management first reported a position in Caribou Biosciences in Q1 2022 and held it in 7 quarters.
Penserra Capital Management's Caribou Biosciences position peaked at $253K in Q3 2022.
144 funds tracked by Wall St. Rank held Caribou Biosciences as of Q4 2023.

Based on Penserra Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.